Catamaran Bio
is a biotechnology company that researches and develops allogeneic CAR-NK cell therapies for the treatment of cancer... Read moreCatamaran Bio
is a biotechnology company that researches and develops allogeneic CAR-NK cell therapies for the treatment of cancer... Read more
2020
PrivateIndependent Company
News
Jan 30, 2024
Endpoints News
Catamaran Bio: CAR NK biotech Catamaran Bio to wind down, will seek partners for cell therapies
Apr 11, 2023
GlobalNewswire
Press Release: Catamaran Bio : Catamaran Bio Announces Preclinical Data from Allogeneic CAR-NK Cell Therapy Pipeline for Solid Tumors to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Mar 14, 2023
Contract Pharma
Catamaran Bio: Catamaran Bio, OmniaBio Partner to Advance Allogeneic CAR-NK Cell Therapies
Jan 04, 2023
Pharamceutical Technology
Catamaran Bio: MaxCyte and Catamaran Bio sign strategic platform licence
Nov 10, 2022
Business Wire
Press Release: Catamaran Bio : Catamaran Bio Presents Preclinical Efficacy Data for Two Allogeneic CAR-NK Cell Therapies for Solid Tumors at SITC 2022 Annual Meeting
May 16, 2022
FirstWord Pharma
Catamaran Bio: Catamaran Bio Presents Preclinical Data Supporting Novel Engineered CAR-NK Cell Therapies For Treating Solid Tumors
May 02, 2022
FirstWord Pharma
Catamaran Bio: Catamaran Bio to Present Preclinical Data at ASGCT Annual Meeting to Support CAR-NK Approach for Solid Tumors
Apr 08, 2022
FirstWord Pharma
Catamaran Bio: Catamaran Bio Presents Preclinical In Vivo Efficacy Data Supporting Advancement of CAT-179, a HER2-targeted Allogeneic CAR-NK Cell Therapy
Mar 14, 2022
FirstWord Pharma
Catamaran Bio: Catamaran Bio Expands Collaboration for CARNK Cell Engineering with the University of Minnesota and Secures an Exclusive Patent License to Next Generation Manufacturing Technologies
Mar 09, 2022
FirstWord Pharma
Catamaran Bio: Catamaran Bio to Present Preclinical Efficacy Data on Allogeneic Solid Tumor CAR-NK Program at AACR Annual Meeting 2022
